NCT07749586Phase 1, phase 2Recruiting

A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors

Study sponsor: Arvinas Inc. · ARVN

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2031-03-31Estimated
Enrollment · participants499Estimated
Source updated2026-11-19Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.